Literature DB >> 27546840

Current Perspectives on Gastric Cancer.

Juan M Marqués-Lespier1, María González-Pons2, Marcia Cruz-Correa3.   

Abstract

Gastric cancer (GC) is third leading cause of cancer-related death. Only 28.3% of new GC cases survive more than 5 years. Although incidence has declined in the United States, an increase is estimated for 2016. Risk factors include sex (risk is higher in men), Helicobacter pylori infection, heredity, and lifestyle. GC is usually diagnosed between the ages of 60-80 years. Prognosis of GC is largely dependent on the tumor stage at diagnosis and classification as intestinal or diffuse type; diffuse-type GC has worse prognosis. Chemoprevention has been shown to decrease risk, but is currently not used clinically.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrophic gastritis; Dysplasia; Gastric cancer; Helicobacter pylori; Intestinal metaplasia

Mesh:

Substances:

Year:  2016        PMID: 27546840      PMCID: PMC4993977          DOI: 10.1016/j.gtc.2016.04.002

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  96 in total

1.  Staging gastritis: an international proposal.

Authors:  Massimo Rugge; Robert M Genta
Journal:  Gastroenterology       Date:  2005-11       Impact factor: 22.682

2.  Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011.

Authors:  Kyu-Won Jung; Young-Joo Won; Hyun-Joo Kong; Chang-Mo Oh; Duk Hyoung Lee; Jin Soo Lee
Journal:  Cancer Res Treat       Date:  2014-04-22       Impact factor: 4.679

3.  The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis.

Authors:  Lisette G Capelle; Annemarie C de Vries; Jelle Haringsma; Frank Ter Borg; Richard A de Vries; Marco J Bruno; Herman van Dekken; Jos Meijer; Nicole C T van Grieken; Ernst J Kuipers
Journal:  Gastrointest Endosc       Date:  2010-04-09       Impact factor: 9.427

4.  Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands.

Authors:  A E Dassen; V E P P Lemmens; L V van de Poll-Franse; G J Creemers; S J Brenninkmeijer; D J Lips; A A M Vd Wurff; K Bosscha; J W W Coebergh
Journal:  Eur J Cancer       Date:  2010-03-08       Impact factor: 9.162

5.  Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study.

Authors:  M Rugge; M de Boni; G Pennelli; M de Bona; L Giacomelli; M Fassan; D Basso; M Plebani; D Y Graham
Journal:  Aliment Pharmacol Ther       Date:  2010-02-23       Impact factor: 8.171

6.  Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries.

Authors:  A A Botterweck; L J Schouten; A Volovics; E Dorant; P A van Den Brandt
Journal:  Int J Epidemiol       Date:  2000-08       Impact factor: 7.196

Review 7.  Gastric cancer: prevention, screening and early diagnosis.

Authors:  Victor Pasechnikov; Sergej Chukov; Evgeny Fedorov; Ilze Kikuste; Marcis Leja
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 9.  Endoscopic gastric cancer screening and surveillance in high-risk groups.

Authors:  Il Ju Choi
Journal:  Clin Endosc       Date:  2014-11-30

10.  Association between Habitual Dietary Salt Intake and Risk of Gastric Cancer: A Systematic Review of Observational Studies.

Authors:  Sheng Ge; Xiaohui Feng; Li Shen; Zhanying Wei; Qiankun Zhu; Juan Sun
Journal:  Gastroenterol Res Pract       Date:  2012-10-22       Impact factor: 2.260

View more
  42 in total

1.  The SOX2OT/miR-194-5p axis regulates cell proliferation and mobility of gastric cancer through suppressing epithelial-mesenchymal transition.

Authors:  Ruqiong Wei; Can Ding; Raquel Alarcòn Rodrìguez; Marìa Del Mar Requena Mullor
Journal:  Oncol Lett       Date:  2018-09-12       Impact factor: 2.967

2.  HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer.

Authors:  Li Wei; Liang Tang; Haiyan Chang; Song Huo; Yan Li
Journal:  Hum Cell       Date:  2019-09-24       Impact factor: 4.174

Review 3.  Changing Trends in Stomach Cancer Throughout the World.

Authors:  Maya Balakrishnan; Rollin George; Ashish Sharma; David Y Graham
Journal:  Curr Gastroenterol Rep       Date:  2017-08

Review 4.  Past and current trends in endoscopic diagnosis for early stage gastric cancer in Japan.

Authors:  Kazuki Sumiyama
Journal:  Gastric Cancer       Date:  2016-10-12       Impact factor: 7.370

5.  The clinical significance of miR-335, miR-124, miR-218 and miR-484 downregulation in gastric cancer.

Authors:  Ali Zare; Alireza Ahadi; Pegah Larki; Mir Davood Omrani; Mohammad Reza Zali; Nasser Malekpour Alamdari; Hamid Ghaedi
Journal:  Mol Biol Rep       Date:  2018-08-31       Impact factor: 2.316

6.  Clinicopathological evaluation of Sox10 expression in diffuse-type gastric adenocarcinoma.

Authors:  Marin Kato; Hiroshi Nishihara; Hideyuki Hayashi; Taichi Kimura; Yusuke Ishida; Lei Wang; Masumi Tsuda; Mishie Ann Tanino; Shinya Tanaka
Journal:  Med Oncol       Date:  2016-12-10       Impact factor: 3.064

7.  Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer.

Authors:  Ebru Esin Yörüker; Metin Keskin; Cemil Burak Kulle; Stefan Holdenrieder; Ugur Gezer
Journal:  Biomed Rep       Date:  2018-06-22

8.  The impact of age on prognosis in patients with gastric cancer: experience in a tertiary care centre.

Authors:  Maan El Halabi; Renee Horanieh; Hani Tamim; Deborah Mukherji; Sara Jdiaa; Sally Temraz; Ali Shamseddine; Kassem Barada
Journal:  J Gastrointest Oncol       Date:  2020-12

9.  Inpatient burden of gastric cancer in the United States.

Authors:  Shantanu Solanki; Raja Chandra Chakinala; Khwaja Fahad Haq; Muhammad Ali Khan; Alina Kifayat; Katherine Linder; Zubair Khan; Uvesh Mansuri; Khwaja Saad Haq; Christopher Nabors; Wilbert S Aronow
Journal:  Ann Transl Med       Date:  2019-12

10.  Clinical significance and biological function of transcriptional repressor GATA binding 1 in gastric cancer: a study based on data mining, RT-qPCR, immunochemistry, and vitro experiment.

Authors:  Hong Wu; Zhiguang Huang; Menglan Huang; Yiwu Dang; Huiping Lu; Xingan Qin; Liang Liang; Lihua Yang; Jie Ma; Gang Chen; Zili Lv
Journal:  Cell Cycle       Date:  2020-10-12       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.